Oppenheimer started coverage on shares of Vaxart (NASDAQ:VXRT – Free Report) in a research report released on Thursday, Marketbeat reports. The brokerage issued an outperform rating and a $4.00 price objective on the biotechnology company’s stock.
Vaxart Stock Performance
VXRT opened at $0.79 on Thursday. The firm’s fifty day moving average is $0.67 and its two-hundred day moving average is $0.90. The firm has a market cap of $139.42 million, a PE ratio of -1.49 and a beta of 0.65. Vaxart has a twelve month low of $0.52 and a twelve month high of $1.54.
Vaxart (NASDAQ:VXRT – Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.12). Vaxart had a negative return on equity of 121.06% and a negative net margin of 920.00%. The business had revenue of $6.40 million for the quarter, compared to the consensus estimate of $65.70 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. Equities analysts forecast that Vaxart will post -0.55 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Vaxart
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Featured Articles
- Five stocks we like better than Vaxart
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Why Are Stock Sectors Important to Successful Investing?
- MarketBeat Week in Review – 8/12 – 8/16
- Canadian Penny Stocks: Can They Make You Rich?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.